3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
59
Neoplasm Metastasis
5
Prostate Cancer Metastatic
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
3
Adenocarcinoma
3
Prostate CA
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Salivary Gland Neoplasms
1
Recurrence
1
Radiation Injuries
1
Prostatic Diseases
1
PSA Level Greater Than 0.03
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Lymphatic Metastasis
1
Intraprostatic Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Gastrointestinal Diseases
1
Interventions
Androgen Antagonists
3
darolutamide
2
Docetaxel
2
relugolix
1
niraparib
1
Prednisone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
×
Androgen Antagonists
×
1 year
×
Clear all
NCT06661122
2026-05-19
HAYATE
Bayer
Recruiting
100 enrolled
NCT06392841
2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2
Withdrawn
NCT07216248
2025-10-29
OPTIMAS
University of Utah
Phase 2
Recruiting
160 enrolled